January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop ...

Heid, a China hawk who helped set technology policy for the congressional committee, is being tapped to be assistant ...

It is well known that WuXi entities have become dangerously entwined with American biotech. BGI Group's genomic data collection and ties to the Chinese military have alarmed national security ...

Find insights on China’s healthcare sector, Thomson Medical Group, Cochlear, and more in the latest Market Talks covering the ...

A PAT roadmap should address data analysis, aggregation, visualization, and the smart utility of those data for greater process understanding.

The WuXi companies have come under scrutiny amid ... contracts with the Beijing Genomics Institute and some Chinese biotechnology entities. As the bill was not enacted under the Biden ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

President Donald Trump plans to nominate Landon Heid, who served on the staff of the House of Representatives' Select ...